CISAPRIDE AND ANAESTHESIA

The risks and benefits of cisapride.

Cisapride and Patient Information Leaflets Letters Correspondance

dinal weights for the analyses in this cycle. However, only cross-sectional and longitudinal weights are calculated in the NLSCY file; bootstrap methodology is not used. In a forthcoming follow-up study of hunger in NLSCY families we compared adjusted prevalence rates of hunger in 1994 and 1996. The population estimates of child hunger in Canada using weights were 1.4% (53 995 children) and 1.6...

Healing and prevention of relapse of reflux oesophagitis by cisapride.

Altogether, 138 patients were included in a study aimed at evaluating the effect of cisapride on healing and relapse of oesophagitis shown endoscopically. In the first phase of the study cisapride was given in an open fashion at 10 mg four times a day for 8 to 16 weeks, and healing was obtained in 69% of patients. Healing occurred later in patients with grades II to IV oesophagitis. The total s...

QT interval in children and infants receiving cisapride.

OBJECTIVES Life-threatening arrhythmias and prolonged QT interval have been reported in adults and children using cisapride, a medication structurally similar to procainamide. Premature infants have reduced activity of cytochrome p-450, the system responsible for metabolism of cisapride, which could lead to QT prolongation. Therefore, we prospectively studied premature infants and children rece...

Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.

In an open, randomized, triple crossover study, the effects of cisapride and sucralfate on the pharmacokinetics of sparfloxacin were assessed. Fifteen healthy volunteers received 400 mg of sparfloxacin as a single oral dose on day 0. In a random order, concomitant doses of 10 mg of cisapride three times daily from day -2 to day 2 and 1 g of sucralfate four times daily from day -2 to day 0 were ...